About
Linc AB generates revenue through long-term share ownership in Nordic life science companies, focusing on pharmaceutical and medical technology sectors. The company invests in both private and public firms, including early-stage drug development and operational medical technology companies. Linc Invest actively supports portfolio companies by collaborating with management, founders, and boards to unlock growth potential and drive expansion. Its industrial network enables strategic participation in nomination committees and development planning. The firm targets Nordic life science product-oriented companies, prioritizing pharmaceuticals and medical technology. Investments span research and operational phases, with drug development typically occurring earlier than in medical technology. Linc AB maintains a hands-on approach as a long-term owner, leveraging its network to assist portfolio companies in achieving ambitious development goals. Linc AB's business model centers on active ownership and strategic partnerships within the Nordic life science ecosystem. It focuses on companies with strong product pipelines, particularly in pharmaceuticals, where investments often occur during initial development stages. The company's role as a supportive shareholder drives value creation through collaborative governance and targeted expansion strategies.
Annual results
Reported figures, SEK
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 9.0M | -399M | -4433.3% | — |
| 2024 | — | 1.3B | — | — |
| 2023 | 3.0M | 619M | 20633.3% | — |
| 2022 | 2.0M | -723M | -36150.0% | — |
| 2021 | 4.0M | -30.0M | -750.0% | — |
LINC.ST in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Linc AB are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.